Mr Herrmann is Chief Financial Officer of ReViral Ltd and Managing Director at Stifel. He is a qualified Chartered Accountant and possesses more than 20 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development stage companies, as well as several investment banks. Mr Herrmann’s last role was as Chief Financial Officer of Silence Therapeutics plc. Prior to joining Silence, Max served as Chief Financial Officer of Intercytex Group plc, a publicly traded company focused on the emerging area of regenerative medicine. Before joining Intercytex, he spent over ten years as a sell side equity analyst, most latterly as Managing Director and Head of European Pharmaceutical and Biotechnology Research at ING. He has also held the position of Financial Controller for US based Onyx Pharmaceuticals Inc. He holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Account with Arthur Andersen.